Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N‑[(2R,3S)‑3‑amino‑2‑hydroxy‑4‑phenylbutyl]‑4‑methoxy‑2,3,6-trimethylbenzenesulfonamide is a synthetic small molecule classified as an experimental compound. It is a sulfonamide derivative structurally related to benzenesulfonamides and features both amino and hydroxy functional groups on a phenylbutane backbone. The compound has been described as an inhibitor of thrombin (prothrombin), suggesting anticoagulant or antithrombotic potential. Its mechanism of action involves direct inhibition of the serine protease activity of thrombin[4][7]. There are no approved therapeutic indications or marketed products containing this molecule; it remains primarily a research tool in biochemical and pharmacological studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]-4-methoxy-2,3,6-trimethylbenzenesulfonamide.